{"id":"bbp-418-ribitol","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3137744","moleculeType":"Small molecule","molecularWeight":"152.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ribitol is a five-carbon sugar alcohol that may serve as a substrate or cofactor in cellular metabolism or immune signaling. As a phase 3 candidate from ML Bio Solutions, BBP-418 likely targets a specific disease pathway, but detailed mechanistic information is not publicly available in standard pharmaceutical databases.","oneSentence":"BBP-418 is a ribitol-based compound that modulates immune or metabolic pathways, though its precise mechanism remains proprietary.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:38.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05775848","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ML Bio Solutions, Inc.","startDate":"2023-05-31","conditions":"Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":969,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BBP-418 (ribitol)","genericName":"BBP-418 (ribitol)","companyName":"ML Bio Solutions, Inc.","companyId":"ml-bio-solutions-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BBP-418, also known as ribitol, is a small molecule being studied as a potential treatment for Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). It is being evaluated in a Phase 3 clinical trial to assess its efficacy and safety in patients with this condition.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}